A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T‐cell leukemia/lymphoma

By  

Cancer Science, Vol. 1347-9032, Iss. 9, 2015-09 ,pp. : 1219-1223

John Wiley & Sons Inc

Access to resources Recommend Favorite

Advanced human T‐cell leukemia virus type 1 carriers and early‐stage indolent adult T‐cell leukemia‐lymphoma are indistinguishable based on CADM1 positivity in flow cytometry

By  

Cancer Science, Vol. 106, Iss. 5, 2015-05 ,pp. : 598-603

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recent advances in the treatment of adult T‐cell leukemia‐lymphomas

By  

Cancer Science, Vol. 106, Iss. 4, 2015-04 ,pp. : 344-351

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of OPB‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

By  

Cancer Science, Vol. 106, Iss. 7, 2015-07 ,pp. : 896-901

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T‐cell leukemia

By  

Cancer Science, Vol. 109, Iss. 1, 2018-01 ,pp. : 103-111

John Wiley & Sons Inc

Access to resources Recommend Favorite